Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2019Author
Kılıçkap, SaadettinDemirci, Umut
Buğdaycı, Fatma
Tural, Deniz
Korkmaz, Taner
Paydaş, Semra
Yılmaz, Coşkun
Tuna, Hande
Sezer, Ahmet
Yeşil Çinkir, Havva
Erman, Münire
Eralp, Yeşim
Çabuk, Devrim
Işıkdoğan, Abdurrahman
Demirkazık, Ahmet
Karaoğlu, Aziz
Yazılıtaş, Doğan
Çay Şenler, Filiz
Yumuk, Perran Fulden
Coşkun, Hatice
Yıldız, İbrahim
Öztop, İlhan
Beypınar, İsmail
Aydın, Kübra
Kaplan, M.
Meydan, Nezih
Ölmez, Ömer Fatih
Seber, Samile
Arslan, Çağatay
Şendur, Mehmet Ali Nahit
Çiçin, İrfan
Metadata
Show full item recordCitation
Kılıçkap, S., Demirci, U., Buğdaycı, F., Tural, D., Korkmaz, T., Paydaş, S. ... Çiçin, İ. (2019). Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey. Journal of Thoracic Oncology içinde (S558-S559. ss.). Elsevier Science. https://doi.org/10.1016/j.jtho.2019.08.1166Abstract
Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK inhibitor. The aim of this study is to evaluate the efficacy and safety of lorlatinib in an Expanded Access Program (EAP) in Turkey.
Method: The EAP was open-label, multicenter, and single-arm. Patients were eligible to receive lorlatinib (100 mg po/day) if they had advanced stage ALK-or ROS1-positive NSCLC and had progressed on crizotinib and/or second generation ALK inhibitors such as ceritinib or alectinib. The primary endpoint was PFS with lorlatinib. Secondary endpoints were objective response rate, overall survival, and safety.
WoS Q Kategorisi
Q1Source
Journal of Thoracic OncologyVolume
14Issue
10Collections
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6631]